eligibility_summary
Eligible: life expectancy ≥12 weeks, ECOG 0–1, measurable disease per RECIST 1.1. Ineligible: prior c‑MET–targeting antibody/bispecific or ADC therapy, hypersensitivity to bevacizumab or to trifluridine/tipiracil–like compounds, or active infection per protocol.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06614192 (Phase 3, randomized, open-label) tests: 1) Telisotuzumab adizutecan (ABBV-400): an anti-c-Met antibody–drug conjugate (ADC). Mechanism: monoclonal antibody targets MET (c-Met) on tumor cells, is internalized, and releases a topoisomerase I inhibitor payload causing DNA damage and cell death, disrupts MET-driven signaling. 2) Comparator: Lonsurf (trifluridine/tipiracil) + bevacizumab. Trifluridine/tipiracil is an oral cytotoxic antimetabolite, trifluridine (a thymidine analog) incorporates into DNA to inhibit tumor proliferation, while tipiracil blocks thymidine phosphorylase to increase trifluridine exposure. Bevacizumab is an anti-VEGF-A monoclonal antibody that inhibits angiogenesis. Targets/pathways: MET-overexpressing colorectal cancer cells (c-Met pathway), DNA synthesis in proliferating tumor cells, and VEGF-driven tumor vasculature.